Clinical Characteristics and Prognostic Factors of Patients with Malignant Melanoma Liver Metastasis
10.3971/j.issn.1000-8578.2025.25.0018
- VernacularTitle:恶性黑色素瘤肝转移患者临床特征和预后因素分析
- Author:
Wangling ZHANG
1
;
Lianjun ZHAO
2
,
3
;
Yu REN
2
,
3
;
Zhengyun ZOU
2
,
3
Author Information
1. Department of Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
2. Department of Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
3. Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Melanoma;
Liver metastasis;
Local therapy;
Immune checkpoint inhibitors;
Antiangiogenic agent
- From:
Cancer Research on Prevention and Treatment
2025;52(8):666-675
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics and prognostic factors of patients with malignant melanoma liver metastasis. Methods The clinical data of patients with melanoma liver metastasis before first-line systemic therapy were retrospectively collected. Kaplan–Meier survival analysis was conducted to evaluate the association of clinical characteristics with overall survival (OS) and progression-free survival (PFS). Prognostic factors associated with PFS and OS were determined through Cox regression analysis. Results A total of 80 patients were included in this study. Six of these patients did not receive systemic or local antitumor therapy after the diagnosis of liver metastasis. Their median survival time after the diagnosis of liver metastasis was 2.3 months. The median OS of the remaining 74 patients was 12.83 months. Cox regression analysis determined that in the patients receiving systemic or local antitumor therapy, age and local treatment were independent prognostic factors for OS; gender and serum NSE levels were independent prognostic factors for systemic PFS and intrahepatic PFS. First-line treatment including immune checkpoint inhibitors (ICIs) may have survival benefits for patients but the difference was not statistically significant (HR=0.716, P=0.255). Among gene mutations, NRAS mutations had the highest rates (11.25%) and were associated with poor prognosis. In addition, BRAF and CKIT mutations were detected in eight (10%) and four (5%) patients, respectively. Conclusion Patients who are younger and receive local treatment have a relatively better prognosis. The first-line ICI therapy may have survival benefits for patients.
